LABORATORY NEWS
-
Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits For Analytical Studies
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India, has sent test kits of the SARAGENE® Bundibugyo Virus Test to a third-party laboratory for evaluation following a request by the India Centre for Cellular and Molecular Platforms ("C-CAMP"), an initiative supported by the India Department of Biotechnology.
- Ozelle Launches O-Cyte 1 At ADLM 2026, Marking A New Step In AI-Powered Hematology
- New Blood Test For Tuberculosis Could Reduce The Spread Of This Top Global Infectious-Disease Killer
- Clinisys Partners With Decisions To Bring Low-Code / No-Code LIMS/LIS Configuration To Laboratory Environments
- Waters Launches Industry's Most Sensitive And Robust Clinical IVD System With Xevo TQ Absolute XR IVD Mass Spectrometer
ARCHIVED NEWSLETTER
- 07.21.26 -- Reassessing Nanoparticle Immunotoxicity: From Well-Established To Novel Approaches
- 07.07.26 -- A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis
- 05.26.26 -- Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics
- 04.21.26 -- Proteomics Tools: A Resurrection
- 04.07.26 -- Navigating GMP Biosafety Challenges In ATMP Manufacturing